Search

Your search keyword '"Mancuso G."' showing total 1,049 results
Start Over Author "Mancuso G."
1,049 results on '"Mancuso G."'

307. Procalcitonin as a marker of nosocomial infections in the neonatal intensive care unit

Author

Chiesa, C., Pacifico, L., Rossi, N., Panero, A., Matrunola, M., and Mancuso, G.

Subjects
Calcitonin -- Measurement, Calcitonin -- Research, Cross infection -- Diagnosis, Nosocomial infections -- Diagnosis, Biological markers -- Research, Neonatal intensive care -- Research, Health care industry
Abstract

Byline: C. Chiesa (1), L. Pacifico (1), N. Rossi (1), A. Panero (1), M. Matrunola (1), G. Mancuso (1) Keywords: Key words Procalcitonin; Nosocomial infection; Neonate Abstract: Objective: To determine accuracy of procalcitonin concentrations for diagnosing nosocomial infections in critically ill neonates.APDesign: Case-control study.APSetting: Neonatal intensive care unit of a teaching hospital.APPatients: Twenty-three neonates with nosocomial infection. Four controls matched for duration of hospital stay and birth date were chosen for each case patient.APMeasurements and results: PCT concentrations were measured by the LUMItest procalcitonin kit at onset of signs of infection and after recovery. Range of PCT concentrations (ng/ml) was 2.0 to 249.1 in case patients and 0.08 to 1.0 in controls (sensitivity and specificity, 100 %). PCT values returned to normal (< 1.0 ng/ml) by day 3 to 7 of appropriate antibiotic therapy.APConclusions: Measurement of PCT concentrations may be useful for early diagnosis and monitoring of infectious complications in neonates during their stay in the neonatal intensive care unit. Author Affiliation: (1) Institute of Pediatrics, La Sapienza University of Rome-Institute of Experimental Medicine CNR, 00161-Rome, Italy Tel.: + 39-06-49-21 84 80 E-mail: PACIFICO@UNIROMA1.it, IT

Published
2000

308. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries

Author

Ljung, R., primary, Aronis-Vournas, S., additional, Kurnik-Auberger, K., additional, Van Den Berg, M., additional, Chambost, H., additional, Claeyssens, S., additional, Van Geet, C., additional, Glomstein, A., additional, Hann, I., additional, Hill, F., additional, Kobelt, R., additional, Kreuz, W., additional, Mancuso, G., additional, Muntean, W., additional, Petrini, P., additional, Rosado, L., additional, Scheibel, E., additional, Siimes, M., additional, Smith, O., additional, and Tusell, J., additional

Published
2000
Full Text
View/download PDF

324. Abstracts of the Summer Meeting 6 June 1996, Louvain-en-Woluwé, Belgium

Author

Gilon, P., primary, Miura, Y., additional, Henquin, J. C., additional, Tytgat, J., additional, Daenens, P., additional, Decostre, V., additional, Maréchal, G., additional, Brichard, S. M., additional, Becker, D. J., additional, Reul, B., additional, Ongemba, L. N., additional, Rousseau, V., additional, Eechaute, W., additional, Dhooghe, W., additional, Calders, P., additional, Gao, N. C., additional, Lacroix, E., additional, Weyne, J., additional, Kaufman, J., additional, Tomasovic, S., additional, Frankenne, F., additional, Boland, A., additional, Delapierre, D., additional, Marechal, D., additional, Dresse, A., additional, Feron, O., additional, Wibo, M., additional, Maleki, M., additional, Zheng, L., additional, Kolar, F., additional, Godfraind, T., additional, Paemeleire, K., additional, Leybaert, L., additional, Lambillotte, C., additional, Nenquin, M., additional, Wechsung, E., additional, Houvenaghel, A., additional, Mancuso, G., additional, Tirelli, E., additional, Vandenput, S., additional, Votion, D., additional, Duvivier, D. H., additional, Art, T., additional, Lekeux, P., additional, Duvivier, H. D., additional, Kelemen, B. S., additional, Van Erck, E., additional, Mountian, I., additional, Missiaen, L., additional, and Van Driessche, W., additional

Published
1996
Full Text
View/download PDF

341. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.

Author

Castaman, G., Coppola, A., Zanon, E., Boeri, E., Musso, M., Siragusa, S., Federici, A. B., Mancuso, G., Barillari, G., Biasoli, C., Feola, G., Franchini, M., Moratelli, S., Gamba, G., Schinco, P., Valdrè, L., Dragani, A., Mazzucconi, G., Tagliaferri, A., and Morfini, M.

Subjects
VON Willebrand disease treatment, VON Willebrand factor, BLOOD coagulation factors, HEMORRHAGE, PHARMACOKINETICS
Abstract

Von Willebrand disease ( VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor ( VWF). Replacement therapy with plasma-derived VWF/factor VIII ( FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced ( VR) formulation of VWF/ FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled patients received Haemate ® P VR according to their needs, and were followed for 24 months. Of the 121 patients enrolled, 25.6% had type 3 VWD and more than 40% had severe disease. All patients were followed for 2 years, for a total of 521 visits. On-demand treatment was given to 61.9% of patients, secondary long-term prophylaxis to 25.6% and prophylaxis for surgery, dental or invasive procedures to 45.5%. The response to treatment was rated as good to excellent in >93-99% of interventions. The new formulation was well tolerated by all patients with no report of drug-related adverse events. The switch to volume-reduced Haemate® P was easy to perform and infusion duration was decreased twofold compared with the previous formulation. Volume-reduced Haemate® P was at least as effective and well-tolerated as the previous formulation. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

342. Wall shear stress and plaque localization in carotid arteries

Author

Arturo Pujia, F. Massimo, P.L. Mattioli, Mancuso G, M.S. De Francheschi, Concetta Irace, A. Crescenzo, Agostino Gnasso, and C. Carallo

Subjects
Materials science, Carotid arteries, Shear stress, Anatomy, Cardiology and Cardiovascular Medicine
Published
1997

344. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP)

Author

Basso, G., primary, Putti, M. C., additional, Cantú-Rajnoldi, A., additional, Saitta, M., additional, Santostasi, T., additional, Santoro, N., additional, Lippi, A., additional, Comelli, A., additional, Felici, L., additional, Favre, C., additional, Mancuso, G. Russo, additional, Guglielmi, C., additional, Paolucci, P., additional, Biondi, A., additional, Rondelli, R., additional, and Pession, A., additional

Published
1992
Full Text
View/download PDF

349. Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review.

Author

CASCIO, A., PERNICE, L. M., BARBERI, G., DELFINO, D., BIONDO, C., BENINATI, C., MANCUSO, G., RODRIGUEZ-MORALES, A. J., and IARIA, C.

Abstract

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome that is often fatal despite treatment. It is caused by a dysregulation in natural killer T-cell function, resulting in activation and proliferation of histiocytes with uncontrolled hemophagocytosis and cytokines overproduction. The syndrome is characterized by fever, hepatosplenomegaly, cytopenias, liver dysfunction, and hyperferritinemia. HLH can be either primary, with a genetic aetiology, or secondary, associated with malignancies, autoimmune diseases, or infections. AIM: To focus on secondary HLH complicating zoonotic diseases. MATERIALS AND METHODS: PubMed search of human cases of HLH occurring during zoonotic diseases was performed combining the terms (haemophagocytic OR haemophagocytosis OR hemophagocytosis OR hemophagocytic OR erythrophagocytosis OR macrophage activation syndrome) with each one of the etiological agents of zoonoses. RESULTS: Among bacterial diseases, most papers reported cases occurring during brucellosis, rickettsial diseases and Q fever. Regarding viral diseases, most of the cases were reported in patients with avian influenza A subtype H5N1. Among the protozoan zoonoses, most of the cases were reported in patients with visceral leishmaniasis. Regarding zoonotic fungi, most of the cases were reported in AIDS patient with histoplasmosis. No cases of secondary HLH were reported in patient with zoonotic helminthes. CONCLUSIONS: Zoonotic diseases are an important cause of HLH. Secondary HLH can delay the correct diagnosis of the zoonotic disease, and can contribute to an adverse outcome. [ABSTRACT FROM AUTHOR]

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results